Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05485350 | Unknown Phase 2

• 1 other identifier: ALTER-L056
• Study Type: interventional
• Target: 32
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will explore the effectiveness and safety of the combination therapy of anlotinib , penpulimab and SBRT in patients with metastatic non-small Cell Lung Cancer (NSCLC)

Conditions

Non-Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Progression-free Survival

  Time from enrollment to first observation of progression (RECIST1.1) or date of death (from any cause)

  Time Frame: up to approximately 2 year

Secondary Outcomes (3)

• Objective response rate

  Time Frame: up to approximately 1 year

• Overall Survival

  Time Frame: up to approximately 2 year

• incidence, type and severity of adverse events

  Time Frame: up to approximately 2 year

Study Arms (1)

Anlotinib combined with SBRT and penpulimab

EXPERIMENTAL

Drug: Anlotinib Hydrochloride; Drug: penpulimab; Radiation: SBRT

Interventions

Anlotinib Hydrochloride DRUG

12 mg/d, d1-14, q3w

Also known as: AL3818, Anlotinib Hydrochloride Capsules, FuKeWei

Anlotinib combined with SBRT and penpulimab

penpulimab DRUG

200mg, ivgtt, d1, q3w

Also known as: AK105

Anlotinib combined with SBRT and penpulimab

SBRT RADIATION

55-180Gy

Anlotinib combined with SBRT and penpulimab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years, no gender limit；
• Histological or cytological diagnosis of stage IV non-small cell lung cancer（NSCLC）
• The patients joined the study voluntarily and signed an informed consent form (ICF). They had good compliance and cooperated with follow-up.
• Patients with advanced NSCLC who have received one or two systemic treatments, and those who are unwilling to accept or cannot tolerate systemic chemotherapy can also be enrolled. If it is a driver gene mutation-positive (EGFR, ALK) patient, it must be accepted after receiving the corresponding targeted therapy resistance or intolerable toxicity, No secondary susceptible mutations were eligible for enrollment.
• Has at least five disseminated lesions for SBRT , and measurable lesion that meets the RECISTv1.1 standard。
• Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status
• The expected survival time ≥ 3 months;
• The functions of important organs meet the following requirements (no blood components and cell growth factors are allowed to be used 2 weeks before the start of the research treatment): Absolute Neutrophil Count (ANC) ≥1.5×10 E+9/L, Hemoglobin (HB) ≥9g/dL, Platelets (PLT)≥90×10 E+9/L, Serum Albumin (ALB)≥2.8g/dL, Total Bilirubin (TBIL) ≤1.5 ULN, ALT、AST≤2.5 UILN(If abnormal liver function is caused by liver metastasis, ≤5 ULN), Serum creatinine sCr≤1.5 ULN, endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula) , Normal thyroid function;
• For female subjects of childbearing potential, a serum pregnancy test should be performed within 7 days prior to the administration of the first study intervention (study drug, radiation therapy) and have a negative result. Subjects are required to agree to use highly effective contraception and continue until at least 120 days after discontinuation of trial treatment

You may not qualify if:

• The lesion has received prior radiotherapy and is not suitable for SBRT;
• Currently participating in interventional clinical research and treatment, or receiving other research drugs or treatment with research equipment within 4 weeks before the first administration;
• Imaging (CT or MRI) shows evidence of tumour invasion of large blood vessels or poorly demarcated blood vessels or the presence of cavities and necrotic lesions in the lungs；
• With active bleeding or perforation or a hereditary or acquired bleeding tendency present, with a daily haemoptysis of ≥2.5mL in the 3 months prior to screening.
• Suffer from active autoimmune diseases that require hormone or immunomodulatory treatment;
• Have received anti-tumor monoclonal antibodies (mAb) within 4 weeks before using the study drug for the first time, or the adverse events caused by the previously received drug have not recovered (ie ≤ grade 1 or reached the baseline level). Note: Except for subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 hair loss, if the subject has undergone major surgery, the toxic reaction and/or complications caused by the surgical intervention must be fully recovered before starting treatment;
• Patients with multiple factors that affect oral medications (eg, inability to swallow, chronic diarrhea, and intestinal obstruction).
• Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
• Suffer from acute or chronic infectious diseases, such as hepatitis B, hepatitis C, tuberculosis, and HIV;
• Suffer from uncontrolled clinical symptoms or diseases of the heart, such as:(1) Heart failure above NYHA II; (2) Unstable angina pectoris; (3) Myocardial infarction occurred within 1 year; (4) Patients with clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention;
• Suffer from high blood pressure and cannot be well controlled by antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg);
• Live vaccines have been vaccinated within 4 weeks before the first use of the study drug.
• Active or previously documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).
• Diagnosed as immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy (dose \>10mg/day prednisone or other equivalent therapeutic hormones), and still within 2 weeks before the first dose continue to use.
• Has an active infection requiring systemic treatment.

Sponsors & Collaborators

• Peking University Third Hospital: lead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

anlotinib; penpulimab

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

hongqing zhuang

CONTACT

0086-13051776232; hongqingzhuang@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 9, 2022
• First Posted: August 3, 2022
• Study Start: September 12, 2022
• Primary Completion: September 21, 2023
• Study Completion: October 15, 2024
• Last Updated: August 3, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share